Eikonizo Therapeutics Announces Publication in Brain Demonstrating Disease-Modifying Potential of Selective HDAC6 Inhibitors in Preclinical Models of ALS and FTD
Eikonizo Therapeutics, a biopharmaceutical company developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases, today announced the advance online publication of its preclinical research in the peer-reviewed journal Brain, demonstrating the therapeutic potential of the company’s highly selective, CNS-penetrant HDAC6 inhibitors in the treatment of neurodegenerative disease, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company will also be presenting a subset of this data at the upcoming ALS Therapy Development Institute (TDI) Summit on October 17, 2025 in an oral presentation, titled “The evolution of HDAC6 as a potential therapeutic target for ALS”.
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
Eikonizo Therapeutics, a biopharmaceutical company dedicated to developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases announced today that it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. In addition to supporting the development of Eikonizo’s lead candidate, EKZ-102, a potential first-in-class, oral, CNS-penetrant, highly selective histone deacetylase 6 (HDAC6) inhibitor, the Novo Nordisk investment will also enable the advancement of novel Eikonizo HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease.
